Evaluation of animal models of Parkinson's disease for neuroprotective strategies

Journal of Neuroscience Methods

Volumn 139, Issue 2, 2004, Pages 121-143

  Emborg, Marina E ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

6 OHDA; Animal models; MPTP; Neuroprotection; Non human primates; Parkinson's disease; Pesticides

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; CATECHOLAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUORINE; FLUORODEOXYGLUCOSE F 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; META TYROSINE; NEUROPROTECTIVE AGENT; NEUROTOXIN; OXIDOPAMINE; RACLOPRIDE; RADIOPHARMACEUTICAL AGENT; RESERPINE; TETRABENAZINE; TRACER; TROPANE DERIVATIVE;

BIOCHEMISTRY; BLINKING; BRAIN FUNCTION; CLINICAL FEATURE; COGNITION; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; HYPOKINESIA; LEWY BODY; MOTOR PERFORMANCE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; REVIEW; ROTATION; TASK PERFORMANCE; TREMOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 5644293405     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2004.08.004     Document Type: Review

References (217)

1. J.E. Ahlskog Parkinson's disease: is the initial treatment established? Curr. Neurol. Neurosci. Rep. 3 2003 289 295
2. J.E. Ahlskog, D.M. Maraganore, R.J. Uitti, and G.R. Uhl Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288 2002 311 313
3. H. Almirall, I. Pigarev, l.C. de, M. Pigareva, M.T. Herrero, and T. Sagales Nocturnal sleep structure and temperature slope in MPTP treated monkeys J. Neural. Transm. 106 1999 1125 1134
4. A.H. Andersen, Z. Zhang, T. Barber, W.S. Rayens, J. Zhang, R. Grondin, P. Hardy, G.A. Gerhardt, and D.M. Gash Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies J. Neurosci. Methods 118 2002 141 152
5. L.E. Annett, S.B. Dunnett, F.L. Martel, D.C. Rogers, R.M. Ridley, H.F. Baker, and C.D. Marsden A functional assessment of embryonic dopaminergic grafts in the marmoset Prog. Brain Res. 82 1990 535 542
6. L.E. Annett, E.M. Torres, D.J. Clarke, Y. Ishida, R.A. Barker, R.M. Ridley, H.F. Baker, and S.B. Dunnett Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age Cell Transplant. 6 1997 557 569
7. K.S. Bankiewicz, E.H. Oldfield, C.C. Chiueh, J.L. Doppman, D.M. Jacobowitz, and I.J. Kopin Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Life Sci. 39 1986 7 16
8. C. Barcia, V. Bautista, A. Sanchez-Bahillo, E. Fernandez-Villalba, J.M. Navarro-Ruis, A.F. Barreiro, Y.P. Poza, and M.T. Herrero Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys Neuroendocrinology 78 2003 118 128
9. J.C. Bensadoun, N. Deglon, J.L. Tseng, J.L. Ridet, A.D. Zurn, and P. Aebischer Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF Exp. Neurol. 164 2000 15 24
10. J.C. Bensadoun, Pereira dA, E.G. Fine, J.L. Tseng, N. Deglon, and P. Aebischer Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors J. Control Release 87 2003 107 115
11. H. Bergman, T. Wichmann, B. Karmon, and M.R. DeLong The primate subthalamic nucleus II. Neuronal activity in the MPTP model of parkinsonism J. Neurophysiol. 72 1994 507 520
12. H. Bergman, A. Feingold, A. Nini, A. Raz, H. Slovin, M. Abeles, and E. Vaadia Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates Trends Neurosci. 21 1998 32 38
13. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations J. Neurol. Sci. 20 1973 415 455
14. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 2000 1301 1306
15. E. Bezard, S. Dovero, C. Imbert, T. Boraud, and C.E. Gross Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice Synapse 38 2000 363 368
16. E. Bezard, J.M. Brotchie, and C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat. Rev. Neurosci. 2 2001 577 588
17. W. Birkmayer, and M. Mentasti Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes) Arch. Psychiatr. Nervenkr 210 1967 29 35
18. A. Bjorklund, D. Kirik, C. Rosenblad, B. Georgievska, C. Lundberg, and R.J. Mandel Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model Brain Res. 886 2000 82 98
19. J.H. Bower, D.M. Maraganore, B.J. Peterson, S.K. McDonnell, J.E. Ahlskog, and W.A. Rocca Head trauma preceding PD: a case-control study Neurology 60 2003 1610 1615
20. A.L. Brownell, B.G. Jenkins, D.R. Elmaleh, T.W. Deacon, R.D. Spealman, and O. Isacson Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease Nat. Med. 4 1998 1308 1312
21. A.L. Brownell, E. Livni, W. Galpern, and O. Isacson In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants Ann. Neurol. 43 1998 387 390
22. P.R. Burkhard, H. Shale, J.W. Langston, and J.W. Tetrud Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method Mov. Disord. 14 1999 754 763
23. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridin Proc. Natl. Acad. Sci. U.S.A. 80 1983 4546 4550
24. P.M. Carvey, Q. Chang, J.W. Lipton, and Z. Ling Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease Front Biosci. 8 2003 s826 s837
25. A.O. Ceballos-Baumann Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT J. Neurol. 250 Suppl. 1 2003 I15 I23
26. D.L. Choi-Lundberg, Q. Lin, Y.N. Chang, Y.L. Chiang, C.M. Hay, H. Mohajeri, B.L. Davidson, and M.C. Bohn Dopaminergic neurons protected from degeneration by GDNF gene therapy Science 275 1997 838 841
27. T.J. Collier, and C.E. Sortwell Therapeutic potential of nerve growth factors in Parkinson's disease Drugs Aging 14 1999 261 287
28. T.J. Collier, B.F. Daley, S. Gyawali, J.W. Lipton, Z.D. Ling, P.M. Carvey, C.E. Sortwell, M.R. Pitzer, S.O. McGuire, A. Fletcher-Turner, D.M. Yurek, L. Leventhal, M.E. Emborg, B. Blanchard, K. Steece-Collier, S. Palfi, J.R. Sladek Jr., and J.H. Kordower Aging and the response to mesostriatal dopamine system lesion in MPTP-treated monkeys Soc. Neurosci. 27 2001 Abstr 749
29. T.J. Collier, K. Steece-Collier, and J.H. Kordower Primate models of Parkinson's disease Exp. Neurol. 183 2003 258 262
30. G.U. Corsini, S. Pintus, C.C. Chiueh, J.F. Weiss, and I.J. Kopin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate Eur. J. Pharmacol. 119 1985 127 128
31. J.N. DaSilva, M.R. Kilbourn, and E.F. Domino In vivo imaging of monoaminergic nerve terminals in normal and MPTP-lesioned primate brain using positron emission tomography (PET) and [11C]tetrabenazine Synapse 14 1993 128 131
32. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
33. G.C. Davis, A.C. Williams, S.P. Markey, M.H. Ebert, E.D. Caine, C.M. Reichert, and I.J. Kopin Chronic Parkinsonism secondary to intravenous injection of meperidine analogues Psychiatry Res. 1 1979 249 254
34. T.M. Dawson, and V.L. Dawson Neuroprotective and neurorestorative strategies for Parkinson's disease Nat. Neurosci. 5 Suppl. 2002 1058 1061
35. D.E. Dluzen Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system J. Neurocytol. 29 2000 387 399
36. D.J. Doudet, J.E. Holden, S. Jivan, E. McGeer, and R.J. Wyatt In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism Synapse 38 2000 105 113
37. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, and S.M. Paul Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 98 2001 14669 14674
38. J.L. Eberling, K.S. Bankiewicz, S. Jordan, H.F. VanBrocklin, and W.J. Jagust PET studies of functional compensation in a primate model of Parkinson's disease NeuroReport 8 1997 2727 2733
39. J.L. Eberling, W.J. Jagust, S. Taylor, J. Bringas, P. Pivirotto, H.F. VanBrocklin, and K.S. Bankiewicz A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes Brain Res. 805 1998 259 262
40. J.L. Eberling, P. Pivirotto, J. Bringas, and K.S. Bankiewicz Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys Exp. Neurol. 165 2000 342 346
41. J.L. Eberling, P. Pivirotto, J. Bringas, J.P. Steiner, J.H. Kordower, Y. Chu, M.E. Emborg, and K.S. Bankiewicz The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys Exp. Neurol. 178 2002 236 242
42. D. Eidelberg, J.R. Moeller, T. Ishikawa, V. Dhawan, P. Spetsieris, T. Chaly, A. Belakhlef, F. Mandel, S. Przedborski, and S. Fahn Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography Neurology 45 1995 1995 2004
43. B.A. Ellenbroek, and A.R. Cools Animal models with construct validity for schizophrenia Behav. Pharmacol. 1 1990 469 490
44. J.E. Ellis, L.D. Byrd, and R.A. Bakay A method for quantitating motor deficits in a nonhuman primate following MPTP-induced hemiparkinsonism and co-grafting Exp. Neurol. 115 1992 376 387
45. J.D. Elsworth, M.S. Lawrence, R.H. Roth, J.R. Taylor, R.B. Mailman, D.E. Nichols, M.H. Lewis, and DE. Redmond Jr. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey J. Pharmacol. Exp. Ther. 259 1991 595 600
46. J.D. Elsworth, J.R. Taylor, J.R. Sladek Jr., T.J. Collier, D.E. Redmond Jr., and R.H. Roth Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment Neuroscience 95 2000 399 408
47. M.E. Emborg, and J.A. Colombo Long-term MPTP-treated monkeys are resistant to GM1 systemic therapy Mol. Chem. Neuropathol. 21 1994 75 82
48. M.E. Emborg, and J.H. Kordower Delivery of therapeutic molecules into the CNS Prog. Brain Res. 128 2000 323 332
49. M.E. Emborg, S.Y. Ma, E.J. Mufson, A.I. Levey, M.D. Taylor, W.D. Brown, J.E. Holden, and J.H. Kordower Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys J. Comp. Neurol. 401 1998 253 265
50. M.E. Emborg, P. Shin, B. Roitberg, J.G. Sramek, Y. Chu, G.T. Stebbins, J.S. Hamilton, P.D. Suzdak, J.P. Steiner, and J.H. Kordower Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys Exp. Neurol. 168 2001 171 182
51. M.E. Emborg, J.W. Tetrud, J. Moirano, W.W. McLaughlin, and K.S. Bankiewicz Rest tremor in rhesus monkeys with MPTP-induced parkinsonism Front Biosci. 8 2003 A148 A154
52. M.E. Emborg, Y. Chu, B. Giasson, V.M. Lee, E. Domino, J. Moirano, M. Evans, T. Kladis, T. Collier, J.H. Kordower, and J. Trojanowski Alpha synuclein expression in MPTP treated monkeys Abst. Am. Soc. Neural Transplant. Repair, Exp. Neurol. 181 2003 190
53. M.E. Emborg-Knott, and E.F. Domino MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose Exp. Neurol. 152 1998 214 220
54. A. Eslamboli, H.F. Baker, R.M. Ridley, and L.E. Annett Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys Exp. Neurol. 183 2003 418 429
55. A. Eslamboli, R.M. Cummings, R.M. Ridley, H.F. Baker, N. Muzyczka, C. Burger, R.J. Mandel, D. Kirik, and L.E. Annett Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus) Exp. Neurol. 184 2003 536 548
56. M.B. Feany, and W.W. Bender A drosophila model of Parkinson's disease Nature 404 2000 394 398
57. F. Federico, I.L. Simone, V. Lucivero, D.M. Mezzapesa, M. de Mari, P. Lamberti, M. Petruzzellis, and E. Ferrari Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes Ital. J. Neurol. Sci. 20 1999 223 229
58. A. Feigin, M. Fukuda, V. Dhawan, S. Przedborski, V. Jackson-Lewis, M.J. Mentis, J.R. Moeller, and D. Eidelberg Metabolic correlates of levodopa response in Parkinson's disease Neurology 57 2001 2083 2088
59. G. Flores, G.K. Wood, D. Barbeau, R. Quirion, and L.K. Srivastava Lewis and Fischer rats: a comparison of dopamine transporter and receptors levels Brain Res. 814 1998 34 40
60. T. Foltynie, S. Sawcer, C. Brayne, and R.A. Barker The genetic basis of Parkinson's disease J. Neurol. Neurosurg. Psychiatry 73 2002 363 370
61. F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, C.L. Busceti, R. Ruffoli, P. Soldani, S. Ruggieri, M.G. Alessandri, and A. Paparelli Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition J. Neurosci. 23 2003 8955 8966
62. S. Forsback, R. Niemi, P. Marjamaki, O. Eskola, J. Bergman, T. Gronroos, M. Haaparanta, A. Haapalinna, J. Rinne, and O. Solin Uptake of 6-[18F]fluoro-l-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease Synapse 51 2004 119 127
63. J.D. Fortman, B.T. Bennett, and Hewett TA The laboratory non-human primate. 1st ed 1998 CRC Press Boca Raton
64. C.R. Freed, J.B. Richards, K.E. Sabol, and M.L. Reite Fetal substantia nigra transplants lead to dopamine cell replacement and behavioural improvement in bonnet monkeys with MPTP induced parkinsonism P.M. Beart G.N. Woodruff D.M. Jackson Pharamacology and functional regulation of dopaminergic neurons 1988 Macmilian London 353 360
65. R.A. Fricker, L.E. Annett, E.M. Torres, and S.B. Dunnett The placement of a striatal ibotenic acid lesion affects skilled forelimb use and the direction of drug-induced rotation Brain Res. Bull. 41 1996 409 416
66. J.J. Frost, A.J. Rosier, S.G. Reich, J.S. Smith, M.D. Ehlers, S.H. Snyder, H.T. Ravert, and R.F. Dannals Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35, 428 reveals marked declines in mild Parkinson's disease Ann. Neurol. 34 1993 423 431
67. J.G. Fox, J. Cohen, F.M. Loew, D. Cohen, and S. Barthold Laboratory animal medicine 1984 Academic Press San Diego p. 91-122
68. D.M. Gash, Z. Zhang, A. Ovadia, W.A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, P.A. Lapchak, F. Collins, B.J. Hoffer, and G.A. Gerhardt Functional recovery in parkinsonian monkeys treated with GDNF Nature 380 1996 252 255
69. C.R. Gerfen, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J. Monsma Jr., and D.R. Sibley D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 250 1990 1429 1432
70. O.S. Gershanik Early onset parkinsonism Front Biosci. 8 2003 568 578
71. Geuna S. Appreciating the difference between design-based and model-based sampling strategies in quantitative morphology of the nervous system. J Comp Neurol 2000;427:333-9. Erratum in: J Comp Neurol 2001;430:145.
72. B.I. Giasson, and V.M. Lee A new link between pesticides and Parkinson's disease Nat. Neurosci. 3 2000 1227 1228
73. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 9 2003 s589 s595
74. A. Giovanni, B.A. Sieber, R.E. Heikkila, and P.K. Sonsalla Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Part 1. Systemic administration J. Pharmacol. Exp. Ther. 270 1994 1000 1007
75. A. Giovanni, P.K. Sonsalla, and R.E. Heikkila Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Part 2. Central administration of 1-methyl-4-phenylpyridinium J. Pharmacol. Exp. Ther. 270 1994 1008 1014
76. M. Goddard, A.P. Signore, R.L. Timpson, and P. Aebischer Functional recovery in hemiparkinsonian primates transplanted with polymer encapsulated PC12 cells Restor. Neurol. Neurosci. 4 1992 169 170
77. C.G. Goetz, S. Leurgans, R. Raman, R. Raman Parkinson Study Group Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease Mov. Disord. 17 2002 283 288
78. D.S. Goldstein, S.T. Li, C. Holmes, and K. Bankiewicz Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease J. Pharmacol. Exp. Ther. 306 2003 855 860
79. B. Gomez-Mancilla, J.F. Latulippe, R. Boucher, and P.J. Bedard Effect of ethosuximide on rest tremor in the MPTP monkey model Mov. Disord. 7 1992 137 141
80. J.T. Greenamyre, G. MacKenzie, T.I. Peng, and S.E. Stephans Mitochondrial dysfunction in Parkinson's disease Biochem. Soc. Symp. 66 1999 85 97
81. J.T. Greenamyre, T.B. Sherer, R. Betarbet, and A.V. Panov Complex I and Parkinson's disease IUBMB Life 52 2001 135 141
82. R. Grondin, W.A. Cass, Z. Zhang, J.A. Stanford, D.M. Gash, and G.A. Gerhardt Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys J. Neurosci. 23 2003 1974 1980
83. P. Hantraye, M. Varastet, M. Peschanski, D. Riche, P. Cesaro, J.C. Willer, and M. Maziere Stable parkinsonian syndrome and uneven loss of striatal dopamine fibers following chronic MPTP administration in baboons Neuroscience 53 1993 169 178
84. B.J. Hoffer, A. Hoffman, K. Bowenkamp, P. Huettl, J. Hudson, D. Martin, L.F. Lin, and G.A. Gerhardt Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo Neurosci. Lett. 182 1994 107 111
85. T.L. Horvath, S. Diano, C. Leranth, L.M. Garcia-Segura, M.A. Cowley, M. Shanabrough, J.D. Elsworth, P. Sotonyi, R.H. Roth, E.H. Dietrich, R.T. Matthews, C.J. Barnstable, and DE. Redmond Jr. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease Endocrinology 144 2003 2757 2760
86. C. Imbert, E. Bezard, S. Guitraud, T. Boraud, and C.E. Gross Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey J. Neurosci. Methods 96 2000 71 76
87. + concentrations and neurotoxicity Life Sci. 40 1987 731 740
88. I. Irwin, K.T. Finnegan, L.E. Delanney, D. Di Monte, and J.W. Langston The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment Brain Res. 572 1992 224 231
89. I. Irwin, L.E. Delanney, T. McNeill, P. Chan, L.S. Forno, G.M. Murphy Jr., D.A. Di Monte, M.S. Sandy, and J.W. Langston Aging and the nigrostriatal dopamine system: a non-human primate study Neurodegeneration 3 1994 251 265
90. V. Jackson-Lewis, M. Jakowec, R.E. Burke, and S. Przedborski Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurodegeneration 4 1995 257 269
91. T.A. Jones, and T. Schallert Overgrowth and pruning of dendrites in adult rats recovering from neocortical damage Brain Res. 581 1992 156 160
92. T.A. Jones, and T. Schallert Use-dependent growth of pyramidal neurons after neocortical damage J. Neurosci. 14 1994 2140 2152
93. G. Jonsson, and C. Sachs Actions of 6-hydroxydopamine quinones on catecholamine neurons J. Neurochem. 25 1975 509 516
94. C.N. Karson, P.A. LeWitt, D.B. Calne, and R.J. Wyatt Blink rates in parkinsonism Ann. Neurol. 12 1982 580 583
95. K. Kazumata, A. Antonini, V. Dhawan, J.R. Moeller, R.L. Alterman, P. Kelly, D. Sterio, E. Fazzini, A. Beric, and D. Eidelberg Preoperative indicators of clinical outcome following stereotaxic pallidotomy Neurology 49 1997 1083 1090
96. C.M. Kearns, and D.M. Gash GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo Brain Res. 672 1995 104 111
97. C.M. Kearns, W.A. Cass, K. Smoot, R. Kryscio, and D.M. Gash GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis J. Neurosci. 17 1997 7111 7118
98. D. Kirik, C. Rosenblad, and A. Bjorklund Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat Exp. Neurol. 152 1998 259 277
99. D. Kirik, B. Georgievska, C. Burger, C. Winkler, N. Muzyczka, R.J. Mandel, and A. Bjorklund Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer Proc. Natl. Acad. Sci. U.S.A. 99 2002 4708 4713
100. D. Kirik, L.E. Annett, C. Burger, N. Muzyczka, R.J. Mandel, and A. Bjorklund Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 100 2003 2884 2889
101. R.L. Klein, M.A. King, M.E. Hamby, and E.M. Meyer Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra Hum. Gene Ther. 13 2002 605 612
102. P. Klivenyi, D. St Clair, M. Wermer, H.C. Yen, T. Oberley, L. Yang, and B.M. Flint Manganese superoxide dismutase overexpression attenuates MPTP toxicity Neurobiol. Dis. 5 1998 253 258
103. S. Kohbata, and B.L. Beaman l-Dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice Infect. Immun. 59 1991 181 191
104. K. Kompoliti Estrogen and Parkinson's disease Front Biosci. 8 2003 391 400
105. B.W. Koningsmark Methods for the counting of neurons W.J.H. Nauta S.O.E. Ebbeson Contemporary research methods in neuroanatomy 1970 Springer-Verlag New York 28 45
106. J.H. Kordower, Y.T. Liu, S. Winn, and D.F. Emerich Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical, and neurochemical analysis Cell Transplant. 4 1995 155 171
107. J.H. Kordower, S. Palfi, E.Y. Chen, S.Y. Ma, T. Sendera, E.J. Cochran, E.J. Cochran, E.J. Mufson, R. Penn, C.G. Goetz, and C.D. Comella Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease Ann. Neurol. 46 1999 419 424
108. J.H. Kordower, M.E. Emborg, J. Bloch, S.Y. Ma, Y. Chu, L. Leventhal, J. McBride, E.Y. Chen, S. Palfi, B.Z. Roitberg, W.D. Brown, J.E. Holden, R. Pyzalski, M.D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Deglon, and P. Aebischer Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease Science 290 2000 767 773
109. H.I. Kornblum, and S.R. Cherry The use of microPET for the development of neural repair therapeutics: studies in epilepsy and lesion models J. Clin. Pharmacol. Suppl. 2001 55S 63S
110. H.I. Kornblum, D.M. Araujo, A.J. Annala, K.J. Tatsukawa, M.E. Phelps, and S.R. Cherry In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET) Nat. Biotechnol. 18 2000 655 660
111. N.W. Kowall, P. Hantraye, E. Brouillet, M.F. Beal, A.C. McKee, and R.J. Ferrante MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons NeuroReport 11 2000 211 213
112. K. Kramer, L. Kinter, B.P. Brockway, H.P. Voss, R. Remie, and B.L. Van Zutphen The use of radiotelemetry in small laboratory animals: recent advances Contemp. Top. Lab. Anim. Sci. 40 2001 8 16
113. R. Kurlan, M.H. Kim, and D.M. Gash Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism Mov. Disord. 6 1991 111 118
114. J.W. Langston The etiology of Parkinson's disease with emphasis on the MPTP story Neurology 47 1996 S153 S160
115. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
116. J.W. Langston, L.S. Forno, C.S. Rebert, and I. Irwin Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyrine (MPTP) in the squirrel monkey Brain Res. 292 1984 390 394
117. J.W. Langston, L.S. Forno, J. Tetrud, A.G. Reeves, J.A. Kaplan, and D. Karluk Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Ann. Neurol. 46 1999 598 605
118. J.W. Langston, M. Quik, G. Petzinger, M. Jakowec, and D.A. Di Monte Investigating levodopa-induced dyskinesias in the parkinsonian primate Ann. Neurol. 47 2000 S79 S89
119. Y.S. Lau, K.L. Trobough, J.M. Crampton, and J.A. Wilson Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice Gen. Pharmacol. 21 1990 181 187
120. D. Le Bihan Looking into the functional architecture of the brain with diffusion MRI Nat. Rev. Neurosci. 4 2003 469 480
121. C.S. Lee, A. Samii, V. Sossi, T.J. Ruth, M. Schulzer, J.E. Holden, J. Wudel, P.K. Pal, R. Fuente-Fernandez, D.B. Calne, and A.J. Stoessl In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann. Neurol. 47 2000 493 503
122. K.L. Leenders, S.M. Aquilonius, K. Bergstrom, P. Bjurling, A.R. Crossman, S.A. Eckernas, A.G. Gee, P. Hartvig, H. Lundqvist, and B. Langstrom Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers Brain Res. 445 1988 61 67
123. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132
124. B.C. Lo, J.L. Ridet, B.L. Schneider, N. Deglon, and P. Aebischer Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 99 2002 10813 10818
125. J. Luthman, and E. Sundstrom No apparent difference in the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the sympathetic system in NMRI and C57BL/6 mice Toxicol. Lett. 54 1990 83 92
126. S. Mandel, O. Weinreb, and M.B. Youdim Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs Trends Pharmacol. Sci. 24 2003 184 191
127. A.B. Manning-Bog, A.L. McCormack, J. Li, V.N. Uversky, A.L. Fink, and D.A. Di Monte The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein J. Biol. Chem. 277 2002 1641 1644
128. E. Maries, B. Dass, T.J. Collier, J.H. Kordower, and K. Steece-Collier The role of alpha-synuclein in Parkinson's disease: insights from animal models Nat. Rev. Neurosci. 4 2003 727 738
129. J.F. Marshall, and A.J. Rosenstein Age-related decline in rat striatal dopamine metabolism is regionally homogeneous Neurobiol. Aging 11 1990 131 137
130. J.W. Marshall, and R.M. Ridley Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species Neurodegeneration 5 1996 275 286
131. W. Maruyama, T. Yamamoto, K. Kitani, M.C. Carrillo, M. Youdim, and M. Naoi Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline Mech. Ageing Dev. 116 2000 181 191
132. K.S. McNaught, and C.W. Olanow Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S73 S84
133. K.S. McNaught, L.M. Bjorklund, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Proteasome inhibition causes nigral degeneration with inclusion bodies in rats NeuroReport 13 2002 1437 1441
134. K.S. McNaught, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Altered proteasomal function in sporadic Parkinson's disease Exp. Neurol. 179 2003 38 46
135. T.H. McNeill, and L.L. Koek Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice Brain Res. 521 1990 107 117
136. M.D. Meglasson, M.A. Connell, J.A. Boller, J.A. Bley, C.A. Simmons, G.J. Wheeler, J. Palandra, B. Rohrs, J.P. McGrath, D.T. Stephenson, and M.E. Emborg Comparison of sumanirole, ropinirole, and levodopa in MPTP-treated squirrel monkeys: behavioral effects of an agonist selective for the D2 Neurology 60 Suppl. 1 2003 P03.097
137. W.P. Melega, J.M. Hoffman, A. Luxen, C.H. Nissenson, M.E. Phelps, and J.R. Barrio The effects of carbidopa on the metabolism of 6-[18F]fluoro-l-dopa in rats, monkeys and humans Life Sci. 47 1990 149 157
138. J.S. Mendez, and B.W. Finn Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats J. Neurosurg. 42 1975 166 173
139. R.S. Miletich, K.S. Bankiewicz, M. Quarantelli, R.J. Plunkett, J. Frank, I.J. Kopin, and G. Di Chiro MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys Ann. Neurol. 35 1994 689 697
140. J.R. Moeller, T. Nakamura, M.J. Mentis, V. Dhawan, P. Spetsieres, A. Antonini, J. Missimer, K.L. Leenders, and D. Eidelberg Reproducibility of regional metabolic covariance patterns: comparison of four populations J. Nucl. Med. 40 1999 1264 1269
141. E.B. Montgomery Jr., W.C. Koller, T.J. LaMantia, M.C. Newman, E. Swanson-Hyland, A.W. Kaszniak, and K. Lyons Early detection of probable idiopathic Parkinson's disease I. Development of a diagnostic test battery Mov. Disord. 15 2000 467 473
142. E.B. Montgomery Jr., K. Lyons, and W.C. Koller Early detection of probable idiopathic Parkinson's disease II. A prospective application of a diagnostic test battery Mov. Disord. 15 2000 474 478
143. C.P. Montoya, L.J. Campbell-Hope, K.D. Pemberton, and S.B. Dunnett The staircase test: a measure of independent forelimb reaching and grasping abilities in rats J. Neurosci. Methods 36 1991 219 228
144. T. Nagatsu, and M. Yoshida An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions Neurosci. Lett. 87 1988 178 182
145. T. Nagatsu, M. Levitt, and S. Udenfriend Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis J. Biol. Chem. 239 1964 2910 2917
146. E. Nurmi, H.M. Ruottinen, V. Kaasinen, J. Bergman, M. Haaparanta, O. Solin, and J.O. Rinne Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT Ann. Neurol. 47 2000 804 808
147. M.C. Obinu, M. Reibaud, V. Blanchard, S. Moussaoui, and A. Imperato Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence Mov. Disord. 17 2002 13 19
148. Y. Oiwa, J.L. Eberling, D. Nagy, P. Pivirotto, M.E. Emborg, and K.S. Bankiewicz Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes Front Biosci. 8 2003 a155 a166
149. M. Olsson, G. Nikkhah, C. Bentlage, and A. Bjorklund Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test J. Neurosci. 15 1995 3863 3875
150. S. Orimo, E. Ozawa, T. Oka, S. Nakade, K. Tsuchiya, M. Yoshimoto, K. Wakabayashi, and H. Takahashi Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA Neurology 57 2001 1140 1141
151. S. Orimo, T. Oka, H. Miura, K. Tsuchiya, F. Mori, K. Wakabayashi, T. Nagao, and M. Yokochi Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy J. Neurol. Neurosurg. Psychiatry 73 2002 776 777
152. M. Orth, and A.H. Schapira Mitochondrial involvement in Parkinson's disease Neurochem. Int. 40 2002 533 541
153. T. Ostenfeld, Y.T. Tai, P. Martin, N. Deglon, P. Aebischer, and C.N. Svendsen Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons J. Neurosci. Res. 69 2002 955 965
154. H.H. Osterburg, H.G. Donahue, J.A. Severson, and C.E. Finch Catecholamine levels and turnover during aging in brain regions of male C57BL/6J mice Brain Res. 224 1981 337 352
155. Y. Ouchi, T. Kanno, H. Okada, E. Yoshikawa, M. Futatsubashi, S. Nobezawa, T. Torizuka, and M. Sakamoto Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study Ann. Neurol. 46 1999 723 731
156. A. Ovadia, Z. Zhang, and D.M. Gash Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys Neurobiol. Aging 16 1995 931 937
157. S. Palfi, L. Leventhal, C.G. Goetz, T. Hantraye, B.Z. Roitberg, J. Sramek, M. Emborg, and J.H. Kordower Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys Mov. Disord. 15 2000 524 530
158. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 287 2002 1653 1661
159. B.D. Pate, T. Kawamata, T. Yamada, E.G. McGeer, K.A. Hewitt, B.J. Snow, T.J. Ruth, and D.B. Calne Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices Ann. Neurol. 34 1993 331 338
160. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates. 2nd ed 1986 Academic Press San Diego
161. I. Perez-Otano, C. Oset, M.R. Luquin, M.T. Herrero, J.A. Obeso, and J. Del Rio MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration Neurosci. Lett. 175 1994 121 125
162. E. Petroske, G.E. Meredith, S. Callen, S. Totterdell, and Y.S. Lau Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment Neuroscience 106 2001 589 601
163. S.L. Pinkston, L. DeLanney, M.E. Emborg, D. Nagy, J.W. Langston, I. Irwin, D. Kutzcher, F. Wu, and K.S. Bankiewicz The development of a new squirrel monkey model of Parkinson's disease Soc. Neurosci. Abst. 21 1995 1256
164. M. Podell, M. Hadjiconstantinou, M.A. Smith, and N.H. Neff Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism Exp. Neurol. 179 2003 159 166
165. K. Pong, and M.M. Zaleska Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases Curr. Drug Target CNS Neurol. Disord. 2 2003 349 356
166. S. Przedborski, and M. Vila The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease Ann. N.Y. Acad. Sci. 991 2003 189 198
167. S. Przedborski, V. Jackson-Lewis, A.B. Naini, M. Jakowec, G. Petzinger, R. Miller, and M. Akram The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety J. Neurochem. 76 2001 1265 1274
168. J.M. Rabey, I. Sagi, M. Huberman, E. Melamed, A. Korczyn, N. Giladi, R. Inzelberg, R. Djaldetti, C. Klein, G. Berecz Rasagiline Study Group Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa Clin. Neuropharmacol. 23 2000 324 330
169. B.M. Ravina, S.C. Fagan, R.G. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson, and J.R. Marler Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment Neurology 60 2003 1234 1240
170. D.E. Redmond Jr., R.H. Roth, and JR. Sladek Jr. MPTP produces classic parkinsonian syndrome in African Green monkeys Soc. Neurosci. Abst. 11 1985 166
171. G.A. Ricaurte, L.E. Delanney, I. Irwin, and J.W. Langston Older dopaminergic neurons do not recover from the effects of MPTP Neuropharmacology 26 1987 97 99
172. E.K. Richfield, M.J. Thiruchelvam, D.A. Cory-Slechta, C. Wuertzer, R.R. Gainetdinov, M.G. Caron, D.A. Di Monte, and H.J. Federoff Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice Exp. Neurol. 175 2002 35 48
173. C. Rosenblad, D. Kirik, B. Devaux, B. Moffat, H.S. Phillips, and A. Bjorklund Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle Eur. J. Neurosci. 11 1999 1554 1566
174. R. Sanchez-Pernaute, A.L. Brownell, and O. Isacson Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration NeuroToxicology 23 2002 469 478
175. A.H. Schapira, and C.W. Olanow Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 291 2004 358 364
176. J.S. Schneider, G. Unguez, A. Yuwiler, S.C. Berg, and C.H. Markham Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) Brain 111 Part 6 1988 1265 1285
177. J.S. Schneider, T.I. Lidsky, T. Hawks, J.C. Mazziotta, and J.M. Hoffman Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion Brain Res. 672 1995 112 117
178. M. Sedelis, K. Hofele, R.K. Schwarting, J.P. Huston, and J.K. Belknap Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine J. Neurosci. 23 2003 8247 8253
179. R.D. Smith, Z. Zhang, R. Kurlan, M. McDermott, and D.M. Gash Developing a stable bilateral model of parkinsonism in rhesus monkeys Neuroscience 52 1993 7 16
180. P.K. Sonsalla, G.D. Zeevalk, L. Manzino, A. Giovanni, and W.J. Nicklas MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats J. Neurochem. 58 1992 1979 1982
181. R.G. Staal, K.A. Hogan, C.L. Liang, D.C. German, and P.K. Sonsalla In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium J. Pharmacol. Exp. Ther. 293 2000 329 335
182. STAIR (Stroke Therapy Academic Industry Roundtable) Recommendations for standards regarding preclinical neuroprotective and restorative drug development Stroke 30 1999 2752 2758
183. K. Steece-Collier, T.J. Collier, P.D. Danielson, R. Kurlan, D.M. Yurek, and JR. Sladek Jr. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats Mov. Disord. 18 2003 1442 1454
184. G. Steg Alpha-rigidity in reserpinized rats Experientia 20 1964 79 80
185. J.P. Steiner, G.S. Hamilton, D.T. Ross, H.L. Valentine, H. Guo, M.A. Connolly, S. Liang, C. Ramsey, J.H. Li, W. Huang, P. Howorth, R. Soni, M. Fuller, H. Sauer, A.C. Nowotnik, and P.D. Suzdak Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models Proc. Natl. Acad. Sci. U.S.A. 94 1997 2019 2024
186. E. Storey, B.T. Hyman, B. Jenkins, E. Brouillet, J.M. Miller, B.R. Rosen, and M.F. Beal 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism J. Neurochem. 58 1992 1975 1978
187. P.C. Su, Y. Ma, M. Fukuda, M.J. Mentis, H.M. Tseng, R.F. Yen, H.M. Liu, J.R. Moeller, and D. Eidelberg Metabolic changes following subthalamotomy for advanced Parkinson's disease Ann. Neurol. 50 2001 514 520
188. C.N. Svendsen, and J.W. Langston Stem cells for Parkinson disease and ALS: replacement or protection? Nat. Med. 10 2004 224 225
189. H. Takatsu, H. Nishida, H. Matsuo, S. Watanabe, K. Nagashima, H. Wada, T. Noda, K. Nishigaki, and H. Fujiwara Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG J. Nucl. Med. 41 2000 71 77
190. N.A. Tatton, and S.J. Kish In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining Neuroscience 77 1997 1037 1048
191. J.R. Taylor, J.D. Elsworth, R.H. Roth, J.R. Sladek Jr., and D.E. Redmond Jr. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys Brain 113 Part 3 1990 617 637
192. J.R. Taylor, R.H. Roth, J.R. Sladek Jr., and D.E. Redmond Jr. Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier Behav. Neurosci. 104 1990 564 576
193. J.R. Taylor, J.D. Elsworth, M.S. Lawrence, J.R. Sladek Jr., R.H. Roth, and DE. Redmond Jr. Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys Exp. Neurol. 158 1999 214 220
194. M. Thiruchelvam, B.J. Brockel, E.K. Richfield, R.B. Baggs, and D.A. Cory-Slechta Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res. 873 2000 225 234
195. M. Thiruchelvam, E.K. Richfield, R.B. Baggs, A.W. Tank, and D.A. Cory-Slechta The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease J. Neurosci. 20 2000 9207 9214
196. H. Thoenen, and J.P. Tranzer Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-Hydroxydopamine Naunyn. Schmiedebergs Arch. Exp. Pathol. Pharmakol. 261 1968 271 288
197. J.L. Tillerson, and G.W. Miller Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism J. Neurosci. Methods 123 2003 189 200
198. J.L. Tillerson, W.M. Caudle, M.E. Reveron, and G.W. Miller Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Exp. Neurol. 178 2002 80 90
199. R.J. Tolwani, M.W. Jakowec, G.M. Petzinger, S. Green, and K. Waggie Experimental models of Parkinson's disease: insights from many models Lab. Anim. Sci. 49 1999 363 371
200. A. Tomac, E. Lindqvist, L.F. Lin, S.O. Ogren, D. Young, B.J. Hoffer, and L. Olson Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo Nature 373 1995 335 339
201. A. Tomac, J. Widenfalk, L.F. Lin, T. Kohno, T. Ebendal, B.J. Hoffer, and L. Olson Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult Proc. Natl. Acad. Sci. U.S.A. 92 1995 8274 8278
202. N. Turjanski, A.J. Lees, and D.J. Brooks In vivo studies on striatal dopamine D1 and D2 site binding in l-dopa-treated Parkinson's disease patients with and without dyskinesias Neurology 49 1997 717 723
203. U. Ungerstedt 6-Hydroxy-dopamine induced degeneration of central monoamine neurons Eur. J. Pharmacol. 5 1968 107 110
204. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 1970 485 493
205. M. Vila, S. Vukosavic, V. Jackson-Lewis, M. Neystat, M. Jakowec, and S. Przedborski Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP J. Neurochem. 74 2000 721 729
206. T.Q. Vu, Z.D. Ling, S.Y. Ma, H.C. Robie, C.W. Tong, E.Y. Chen, J.W. Lipton, and P.M. Carvey Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine J. Neural Transm. 107 2000 159 176
207. R.L. Watts, R.A. Bakay, C.J. Herring, K.M. Sweeney, H.J. Colbassani, A. Mandir, L.D. Byrd, and P.M. Iuvone Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys Prog. Brain Res. 82 1990 581 591
208. T. Wichmann, H. Bergman, P.A. Starr, T. Subramanian, R.L. Watts, and M.R. DeLong Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates Exp. Brain Res. 125 1999 397 409
209. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186
210. H. Wilms, J. Sievers, and G. Deuschl Animal models of tremor Mov. Disord. 14 1999 557 571
211. I.Q. Whishaw, K. Li, P.A. Whishaw, B. Gorny, and G.A. Metz Distinct forelimb and hind limb stepping impairments in unilateral dopamine-depleted rats: use of the rotorod as a method for the qualitative analysis of skilled walking J. Neurosci. Methods 126 2003 13 23
212. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 2002 1763 1771
213. L. Yang, S. Sugama, J.W. Chirichigno, J. Gregorio, S. Lorenzl, D.H. Shin, S.E. Browne, Y. Shimizu, T.H. Joh, M.F. Beal, and D.S. Albers Minocycline enhances MPTP toxicity to dopaminergic neurons J. Neurosci. Res. 74 2003 278 285
214. Z. Zhang, A. Andersen, C. Smith, R. Grondin, G. Gerhardt, and D. Gash Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging J. Gerontol. A: Biol. Sci. Med. Sci. 55 2000 B473 B480
215. J. Zhang, F.R. Qu, A. Nakatsuka, T. Nomura, M. Nagai, and M. Nomoto Pharmacokinetics of l-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 993 2003 54 58
216. M.J. Zigmond, and E.M. Stricker Animal models of parkinsonism using selective neurotoxins: clinical and basic implications Int. Rev. Neurobiol. 31 1989 1 79
217. A. Zuddas, G.U. Corsini, S. Schinelli, J.N. Johannessen, U. di Porzio, and I.J. Kopin MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra Brain Res. 501 1989 1